Clinical trials: Systemic Sclerosis Pulmonary, active
IgG4 Related Disease, Systemic Sclerosis (SSc)
Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement
Immune-mediated inflammatory diseases (IMIDs) are systemic inflammatory disorders driven by dysregulated immune responses that can affect multiple organs, including the lungs.
- Trial name
- NCT07806045
- Testing
- nebulized human umbilical cord mesenchymal stromal cell-derived extracellular vesicles
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Qiubai Li
Scleroderma, Diffuse, Scleroderma, Systemic
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary…
- Conditions
- Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic
- Trial name
- NCT02682511
- Testing
- Oral Ifetroban
- Where
- 13 sites in United States, India
- Volunteers
- 34 people
- Sponsor
- Cumberland Pharmaceuticals
Interstitial Lung Disease
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
This is a 2-Part study with Part A, a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD.
- Trial name
- NCT05892614
- Testing
- efzofitimod 450 mg, efzofitimod 270 mg
- Where
- 15 sites in United States
- Volunteers
- 25 people
- Sponsor
- aTyr Pharma, Inc.
Interstitial Lung Disease With Systemic Sclerosis
Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis
The goal of this clinical trial is to evaluate the efficacy on lung function after 24 weeks of rituximab + MMF combination comparatively to placebo + MMF combination in patients with SSc-ILD severe at the initial assessment or at…
- Trial name
- EVER-ILD 3 (NCT06549231)
- Testing
- Rituximab
- Where
- France
- Volunteers
- 102 people
- Sponsor
- University Hospital, Tours
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
- Conditions
- Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease
- Trial name
- NCT06329401
- Testing
- AP01
- Where
- 154 sites in United States, Argentina and 12 more
- Volunteers
- 398 people
- Sponsor
- Avalyn Pharma Inc.
Connective Tissue Diseases, Interstitial Lung Disease
Connective Tissue Diseases and Lung Manifestations
Despite a number of prospective studies already initiated in the past years, the current epidemiology and course of interstitial lung disease (ILD) and pulmonary hypertension (PH) in patients with connective tissue disease (CTD)…
- Conditions
- Connective Tissue Diseases, Interstitial Lung Disease, Systemic Sclerosis
- Trial name
- Colipris (NCT04095351)
- Testing
- Pulmonary function test, Imaging, Blood sampling
- Where
- Austria
- Volunteers
- 120 people
- Sponsor
- Medical University Innsbruck
Systemic Sclerosis Associated Interstitial Lung Disease, Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD)
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease
This study was conducted in a randomized, double-blind, placebo-controlled design to evaluate the efficacy and safety of Genakumab injection in the treatment of CTD-ILD including Rheumatoid Arthritis associated Interstitial Lung…
- Conditions
- Systemic Sclerosis Associated Interstitial Lung Disease, Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD), Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
- Trial name
- NCT06189495
- Testing
- GenSci048
- Where
- 4 sites in China
- Volunteers
- 30 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Interstitial Lung Disease (ILD), Idiopathic Pulmonary Fibrosis (IPF)
Finger Versus Earlobe Pulse Oximetry During the 6-Minute Walk Test in Interstitial Lung Disease
The OXISITE-ILD study is a prospective, multicenter, observational study designed to evaluate the agreement between finger (digital) and earlobe (auricular) pulse oximetry for measuring oxygen saturation (SpO2) during the…
- Conditions
- Interstitial Lung Disease (ILD), Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis, Connective Tissue Disease-Associated Interstitial Lung Disease
- Trial name
- OXISITE-ILD (NCT07723872)
- Testing
- Dual-site pulse oximetry (finger and earlobe)
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Hospital de Granollers
Scleroderma, Systemic, Fibrosis; Skin
Western Sweden Systemic Sclerosis Project
The main aim of the project is to identify key-factors involved in the development and progression of Systemic Sclerosis (SSc), a chronic invalidating rheumatic disease characterized by high mortality and insufficient treatment…
- Conditions
- Scleroderma, Systemic, Fibrosis; Skin, Fibrosis Lung, Interstitial Lung Disease Due to Systemic Disease
- Trial name
- WESST (NCT07345052)
- Testing
- No Intervention: Observational Cohort
- Where
- Sweden
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sahlgrenska University Hospital
PHTN in Scleroderma Patients
Pulmonary Hypertension Screening in Scleroderma
Screening for pulmonary hypertension in scleroderma patients
- Trial name
- NCT07186439
- Volunteers
- 35 people
- Sponsor
- Assiut University
Pulmonary Hypertension, Systemic Sclerosis (SSc)
Multicenter Study on the Development of Pulmonary Arterial Hypertension Screening Models Based on Artificial Intelligence for Patients With Systemic Sclerosis
Pulmonary Arterial Hypertension (PAH) is a rare and severe condition that can be associated with Systemic Sclerosis (SSc), significantly worsening the prognosis of the latter disease.
- Conditions
- Pulmonary Hypertension, Systemic Sclerosis (SSc), Systemic Sclerosis-Associated PAH
- Trial name
- ARENAS (NCT07236970)
- Where
- 5 sites in Spain
- Volunteers
- 350 people
- Sponsor
- Alejandro Cruz Utrilla
Systemic Sclerosis, Scleroderma
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis.
- Trial name
- DAISY (NCT05925803)
- Testing
- Anifrolumab (blinded), Anifrolumab (unblinded, open label)
- Where
- 150 sites in United States, Austria and 21 more
- Volunteers
- 314 people
- Sponsor
- AstraZeneca
Progressive Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
- Trial name
- NCT06025578
- Testing
- BMS-986278
- Where
- 459 sites in United States, Argentina and 33 more
- Volunteers
- 1,057 people
- Sponsor
- Bristol-Myers Squibb
Systemic Sclerosis With Lung Involvement, Systemic Sclerosis
Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease
The goal of this pilot study is to assess the feasibility of a larger study on the efficacy of mycophenolate mofetil in people diagnosed with systemic sclerosis with mild lung involvement.
- Conditions
- Systemic Sclerosis With Lung Involvement, Systemic Sclerosis, Interstitial Lung Disease
- Trial name
- SSc-mILD (NCT05785065)
- Testing
- Mycophenolate Mofetil
- Where
- 3 sites in Canada
- Volunteers
- 35 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.
- Trial name
- ATHENA-SSc-ILD (NCT05270668)
- Testing
- Tulisokibart, Companion diagnostic ( CDx)
- Where
- 95 sites in United States, Argentina and 18 more
- Volunteers
- 154 people
- Sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension
Hormonal, Metabolic, and Signaling Interactions in PAH
Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease.
- Conditions
- Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Scleroderma Associated Pulmonary Arterial Hypertension, Appetite Suppressant Associate PAH
- Trial name
- NCT01884051
- Where
- United States
- Volunteers
- 1,899 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Systemic Sclerosis, Pulmonary Arterial Hypertension
Extracellular Vesicle Dynamics Predicting Vascular Complications and Treatment Response in Systemic Sclerosis
Systemic sclerosis is a multisystem autoimmune disease characterized by vascular dysfunction, immune dysregulation, and progressive tissue fibrosis.
- Conditions
- Systemic Sclerosis, Pulmonary Arterial Hypertension, Digital Ulcers, Vascular Complications
- Trial name
- EVOLVE-SSc (NCT07717060)
- Testing
- Blood sampling, nailfold capillaroscopy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Refractory Lupus Nephritis, Systemic Sclerosis
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
This is a single-center, open-label, non-randomized, single-arm clinical trial. Patients with refractory lupus neritis (SLE-LN), systemic sclerosis (SSc), primary Sjogren syndrome combined with pulmonary artery hypertension…
- Conditions
- Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension, Other Autoimmune Diseases (AID)
- Trial name
- NCT06947460
- Testing
- CD19-BCMA CAR-T cells infusion
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Beijing GoBroad Hospital
Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lung disease (SSc-ILD).
- Trial name
- BLISSc-ILD (NCT05878717)
- Testing
- Belimumab
- Where
- 134 sites in United States, Argentina and 16 more
- Volunteers
- 300 people
- Sponsor
- GlaxoSmithKline
Interstitial Lung Diseases, Systemic Sclerosis Associated Interstitial Lung Disease
A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis
This post-approval registry study is planned to generate data to address remaining questions on long-term effectiveness and to better characterize longer term beneficial effects of Nintedanib in patients with systemic sclerosis…
- Trial name
- NCT07080125
- Testing
- Ofev®
- Where
- Switzerland
- Volunteers
- 2,000 people
- Sponsor
- Boehringer Ingelheim